Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $9.75 Consensus PT from Analysts

by · The Markets Daily

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) has been given a consensus rating of “Moderate Buy” by the six brokerages that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $9.75.

A number of equities analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Aclaris Therapeutics in a research note on Monday, October 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday.

View Our Latest Research Report on ACRS

Institutional Trading of Aclaris Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Millennium Management LLC raised its position in shares of Aclaris Therapeutics by 111.0% in the first quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock valued at $6,325,000 after buying an additional 2,175,101 shares in the last quarter. Geode Capital Management LLC increased its stake in Aclaris Therapeutics by 108.4% during the 2nd quarter. Geode Capital Management LLC now owns 2,464,779 shares of the biotechnology company’s stock worth $3,501,000 after acquiring an additional 1,282,042 shares during the period. Acadian Asset Management LLC raised its holdings in Aclaris Therapeutics by 10.9% in the 2nd quarter. Acadian Asset Management LLC now owns 2,433,850 shares of the biotechnology company’s stock valued at $3,453,000 after acquiring an additional 238,659 shares in the last quarter. Palo Alto Investors LP lifted its position in shares of Aclaris Therapeutics by 12.7% during the 3rd quarter. Palo Alto Investors LP now owns 1,566,840 shares of the biotechnology company’s stock valued at $2,977,000 after acquiring an additional 176,812 shares during the period. Finally, Citadel Advisors LLC grew its holdings in shares of Aclaris Therapeutics by 25.3% during the 3rd quarter. Citadel Advisors LLC now owns 1,432,677 shares of the biotechnology company’s stock worth $2,722,000 after purchasing an additional 288,871 shares in the last quarter. Institutional investors own 98.34% of the company’s stock.

Aclaris Therapeutics Stock Up 1.9%

ACRS opened at $3.27 on Thursday. Aclaris Therapeutics has a 12-month low of $1.05 and a 12-month high of $3.66. The business has a 50 day moving average of $2.39 and a 200-day moving average of $1.92. The stock has a market cap of $354.30 million, a price-to-earnings ratio of -2.37 and a beta of 0.62.

Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.01. The business had revenue of $3.30 million during the quarter, compared to the consensus estimate of $1.59 million. Aclaris Therapeutics had a negative return on equity of 39.73% and a negative net margin of 900.01%. As a group, analysts expect that Aclaris Therapeutics will post -0.82 earnings per share for the current year.

Aclaris Therapeutics Company Profile

(Get Free Report)

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.

Further Reading